<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852024000100001</article-id>
<article-id pub-id-type="doi">10.48193/nfqbtm59</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Alteraciones bioquímicas y síndromes paraneoplásicos en pacientes con cáncer renal]]></article-title>
<article-title xml:lang="en"><![CDATA[Biochemical alterations and paraneoplasic syndromes in patients with renal carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-García-Villa]]></surname>
<given-names><![CDATA[Patricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Badillo-Silva]]></surname>
<given-names><![CDATA[Fernanda Monserrat]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes-Acquart]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional Autónoma de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<volume>84</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852024000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852024000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852024000100001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El cáncer renal puede presentarse con manifestaciones paraneoplásicas y alteraciones bioquímicas al diagnóstico. Es frecuente que el diagnóstico se retrase a consecuencia de estas alteraciones bioquímicas. Un 20 % de pacientes con cáncer renal pueden presentar manifestaciones paraneoplásicas.  Material y métodos:  Estudio retrospectivo de pacientes operados de cáncer renal del 2015 al 2022. Se obtuvieron datos demográficos, clínicos, de laboratorio y patológicos Se realizó un análisis descriptivo.  Resultados:  Se revisaron 65 expedientes. Prevalencia de hombres de 72.3 %. La edad media fue 66 años. El carcinoma de células renales se presentó en 70 %. El 34.4 % tuvo anemia. La DHL se elevó en 9.5 %. Hubo hipercalcemia en 7.8 %. La GGT se elevó en 21.4 %. La fosfatasa alcalina se elevó en 29.2 %. 13 % mostró hipoalbuminemia. La velocidad de sedimentación globular se elevó en 75 %. El tiempo de protrombina se elevó en 9.1%. El índice neutrófilos-linfocitos se encontró alto en 33%.  Discusión:  Nuestros resultados demográficos coinciden con los descritos en la literatura. Encontramos coincidencias en alteraciones bioquímicas como anemia, velocidad de sedimentación globular, policitemia, hipertensión, pruebas de función hepática, hipoalbuminemia y tiempos de protrombina. Contrasta el bajo porcentaje de hipercalcemia en nuestra población. El índice neutrófilos leucocitos mostró relación con el grado de Fuhrman.  Conclusión:  El cáncer renal es una neoplasia que se acompaña de alteraciones bioquímicas que constituyen síndromes paraneoplásicos diversos. Su diagnóstico y manejo deberán individualizarse. La población mexicana con cáncer renal presenta características bioquímicas que coinciden con cifras descritas en la literatura internacional.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Renal carcinoma can show biochemical and paraneoplasic alterations at the moment of its diagnosis. Its diagnosis can be delayed due to these biochemical alterations. About 20 % of patients with renal carcinoma can have paraneoplasic syndromes or biochemical alterations.  Method:  We reviewed the information of patients treated with nephrectomy for renal cell carcinoma between 2015 and 2022. We analyzed demographic, clinical and oncological variables. We performed a retrospective, descriptive, analytical study.  Results:  We reviewed 65 files. Prevalence in males was higher with 72.3 %. Age mean was 66 years. Renal cell carcinoma was found in 70 % of patients. 34.4 % presented with anemia, LDH was elevated in 9.5 %. Hypercalcemia presented in 7.8 %. GGT was elevated in 21.4 %. Alcaline phosphatase was elevated in 29.2 %. 13 % showed hipoalbuminemia. Globular sedimentation rate was high in 75 %. Prothrombin time was high in 9.1 %. Neutrophil-lymphocyte ratio (NLR) was high in 33 %.  Conclusions:  Renal carcinoma is a pathology that can show biochemical alterations and different paraneoplasic syndromes. Diagnosis and management must be individualized. Mexican population shows similar biochemical alterations compared to the data reported in international literature.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[renal carcinoma]]></kwd>
<kwd lng="en"><![CDATA[paraneoplasic syndromes]]></kwd>
<kwd lng="en"><![CDATA[biochemical alterations]]></kwd>
<kwd lng="es"><![CDATA[cáncer renal]]></kwd>
<kwd lng="es"><![CDATA[síndromes paraneoplásicos]]></kwd>
<kwd lng="es"><![CDATA[alteraciones bioquímicas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linehan]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Ricketts]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications]]></article-title>
<source><![CDATA[Nature Reviews Urology]]></source>
<year>2019</year>
<volume>16</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>539-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Belldegrun]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Bui]]></surname>
<given-names><![CDATA[MHT]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Dorey]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2003</year>
<volume>170</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1742-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palapattu]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Kristo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rajfer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma]]></article-title>
<source><![CDATA[Reviews in Urology]]></source>
<year>2002</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>163-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muggia]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of cancer-related hypercalcemia: epidemiology and etiology]]></article-title>
<source><![CDATA[Seminars in Oncology]]></source>
<year>1990</year>
<volume>17</volume>
<numero>2^s5</numero>
<issue>2^s5</issue>
<supplement>5</supplement>
<page-range>3-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mundy]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Ibbotson]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Souza]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Flier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>1984</year>
<volume>310</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>1718-27</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chasan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Pothel]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Huben]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management and prognostic significance hypercalcemia in renal cell carcinoma]]></article-title>
<source><![CDATA[Urology]]></source>
<year>1989</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>167-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Eide]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fryjordet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypernephroma and Hypertension]]></article-title>
<source><![CDATA[Acta Medica Scandinavica]]></source>
<year>1981</year>
<volume>209</volume>
<numero>1-6</numero>
<issue>1-6</issue>
<page-range>121-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindop]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renin in renal cell carcinoma--an immunocytochemical study using an antibody to pure human renin]]></article-title>
<source><![CDATA[Journal of Clinical Pathology]]></source>
<year>1984</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-31</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchner]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Braren]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Hollifield]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal Carcinoma Discovered Incidentally by Arteriography During Evaluation for Hypertension]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>1976</year>
<volume>115</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>643-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Sheps]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Bernatz]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[DeWeerd]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal arteriovenous fistula]]></article-title>
<source><![CDATA[The American Journal of Medicine]]></source>
<year>1964</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>499-513</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sufrin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mirand]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hormones in renal cancer]]></article-title>
<source><![CDATA[Transactions of the American Association of Genito-Urinary Surgeons]]></source>
<year>1976</year>
<volume>68</volume>
<page-range>115-20</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kranidiotis]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Voidonikola]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasiou-Nana]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stauffer&#8217;s syndrome as a prominent manifestation of renal cancer: a case report]]></article-title>
<source><![CDATA[Cases Journal]]></source>
<year>2009</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanous]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Alsaud]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoud]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Yassin]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Rare Presentation of Stauffer&#8217;s Syndrome Associated with Renal Cell Carcinoma]]></article-title>
<source><![CDATA[Case Reports in Oncology]]></source>
<year>2020</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>742-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tashjian]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostaglandins, Hypercalcemia and Cancer]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>1975</year>
<volume>293</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>1317-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blay]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Wijdenes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Menetrier-Caux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schemann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Négrier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma]]></article-title>
<source><![CDATA[International Journal of Cancer]]></source>
<year>1997</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>424-30</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ikuerowo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ojewuyi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Omisanjo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Abolarinwa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bioku]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paraneoplastic syndromes and oncological outcomes in renal cancer]]></article-title>
<source><![CDATA[Nigerian Journal of Clinical Practice]]></source>
<year>2019</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1271</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fichman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bethune]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of neoplasms on renal electrolyte function]]></article-title>
<source><![CDATA[Annals of the New York Academy of Sciences]]></source>
<year>1974</year>
<volume>230</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>448-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strum]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remote recurrence of renal cell carcinoma]]></article-title>
<source><![CDATA[Urology]]></source>
<year>1984</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-70</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
